HENDERSON JOHN T 4

What Happened
John T. Henderson, a director of Cytokinetics, received 325 shares of CYTK common stock on April 15, 2026. The shares were granted as director compensation under the company's Director Equity in Lieu of Cash Retainer Program at an effective price/value of $65.37 per share, totaling approximately $21,245. This transaction is an award/acquisition (code A) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-04-15
• Transaction type/code: Award/Acquisition (A)
• Shares granted: 325 at $65.37 per share — total value ≈ $21,245
• Vesting/status: Shares are fully vested (per filing footnote)
• Shares owned after transaction: Not specified in this filing
• Footnote: Granted pursuant to Director Equity in Lieu of Cash Retainer Program; fully vested (F1)
• Filing timeliness: Report filed on 2026-04-15 (no late-filing indication)

Context
This was a compensation award to a director (equity in lieu of cash retainer). Such awards are routine forms of director compensation and do not by themselves indicate insider buying or selling sentiment. Because the shares are fully vested, there are no additional vesting conditions tied to this grant.